2023-503295-25-00招募中3 期
A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY Study.
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 108
- 试验地点
- 19
- 主要终点
- The primary endpoint of the phase II part is the 12-month progression-free survival (PFS) rate: the proportion of patients alive and free from progression/post-resection recurrence by 12-months timepoint from randomization (to be considered as primary endpoint in the phase II part of the study and as secondary endpoint in the phase III part of the study).
研究概览
简要总结
Primary objective of this study is to evaluate the efficacy of neoadjuvant GAP followed by surgery as compared to upfront surgical approach in terms of 12-month progression-free survival (PFS).
研究设计
- 分配方式
- Randomized
- 主要目的
- Phase III period
- 盲法
- None
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Patient able and willing to provide written informed consent and to comply with the study protocol and with the planned surgical procedures.
- •Female and male patients >= 18 years and < 75 years.
- •Histologically or cytologically confirmed non metastatic resectable carcinoma of biliary tract (BTC), including gallbladder carcinoma (GBC), intrahepatic, periperihilar or distal Cholangiocarcinoma (CCA). Mixed tumor entities with hepatocellular carcinoma and ampullary cancers are excluded.
- •Availability of a tumoral sample
- •ECOG performance status of 0-
- •No prior tumor resection for BTC.
- •Exclusion of distant metastases by CT or MRI of abdomen, pelvis, and thorax and PET scan.
- •Technically resectable BTC as per local Multidisciplinary Team (MDT) assessment, including a core team with at least one medical oncologist, one surgeon, one radiologist, one endoscopist/gastroenterologist and one pathologist, all with expertise > 3 years on biliary tract cancer and hepatobiliary oncology..
- •High risk for recurrence defined as the presence of at least one of the following risk features, as evaluated at baseline (pre-surgery)
- •Negative serum pregnancy test within 7 days of starting study treatment in premenopausal women and women <1 year after the onset of menopause.
- •A participant must agree not to donate eggs/sperm for future use for the purposes of assisted reproduction during the study and for a period of 7 months after receiving the last dose of study treatment. Female and male participants should consider preservation of eggs/sperm prior to study treatment as anti-cancer treatments may impair fertility.
- •Estimated life expectancy > 3 months.
- •Adequate baseline hematologic function characterized by the following at screening: a) ANC >=1.5x10^9/L, b) platelets >= 100x10^9/L, c) hemoglobin >=9g/dl. Note: prior transfusions for patients with low hemoglobin are allowed.
- •Adequate liver function characterized by the following at screening: a) Serum total bilitubin <= 1.5xULN and < 2mg/dL.Note: Subjects with Serum total bilirubin >=1.5xULN and conjugated bilirubin <=40% of total bilirubin are allowed. b) Serum transaminases (AST and/or ALT) < 3 x ULN.
- •Adequate renal function, i.e. serum creatinine <= 1.5 institutionalULN and calculated by Cockroft-Gault formula or directly measured creatinine clearance >= 50mL/min
- •Adequate coagulation functions as defined by International Normalized Ratio (INR) <= 1.5,and a partial thromboplastin time (PTT) <= 5 seconds above the ULN (unless receiving anticoagulation therapy).
- •No presence of complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency with DPYD gene testing mandatory at screening as per national guidelines
- •Females of childbearing potential must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V of the full protocol, during the treatment period and for at least 7 months after the last administration of study treatments.
- •Males must agree to remain abstinent (refrain from sexual intercourse) or use highly effective contraceptive methods, as defined in APPENDIX V of the full protocol.
排除标准
- •Known allergy or hypersensitivity to cisplatin, gemcitabine, nab-paclitaxel or fluoropyrimidine and their excipients.
- •Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- •Pregnant or breast-feeding patient, or patient is planning to become pregnant within 7 months after the end of treatment.
- •Any other concurrent antineoplastic treatment including radiotherapy.
- •Previous or concurrent systemic (eg cytotoxic or targeted or other experimental drugs) therapy for BTC.
- •Prior surgery or locoregional therapy for BTC.
- •Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or IV, unstable angina pectoris, history of myocardial infarction in the last three months, significant arrhythmia).
- •Presence of psychiatric disorder precluding understanding of information of trial related topics and giving informed consent.
- •Any serious underlying medical conditions (judged by the investigator), that could impair the ability of the patient to participate in the trial
- •Presence of complete dihydropyrimidine dehydrogenase (DPD) enzyme deficiency with DPYD gene testing mandatory at screening as per national guidelines.
- •Rare hereditary problems of galactose intolerance, total lactase deficiency or glucosegalactose malabsorption.
- •Any known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry except for curatively treated basal cell carcinoma of the skin, in situ carcinoma of the cervix, and prostate cancer.
- •Locally unresectable tumor according to local MDT (including radiological evidence suggesting inability to resect with curative intent whilst maintaining adequate vascular inflow and outflow, and sufficient future liver remnant).
- •Evidence of distant metastases at any site.
- •Tumors requiring multi-step surgical procedures such as two-stage hepatectomy or Associating Liver Partition and Portal vein Ligation for Staged hepatectomy (ALPPS) due to liver volumetry-based assessment of anticipated inadequate future liver remnant.
- •Cirrhosis at a level of Child-Pugh B (or worse) or cirrhosis (any degree) and a history of hepatic decompensation in the year before enrolment.
- •Know active uncontrolled hepatitis B or hepatitis C. Patients with a past or resolved HBV infection are eligible. Patients with chronic disease controlled by antiviral therapy or requiring prophylactic treatment are eligible.
- •Chronic or current active infectious disease requiring systemic antibiotics or antifungal treatment within 2 weeks prior to enrollment.
- •Known uncontrolled HIV infection. HIV-positive patients are eligible if their CD4+ cell count amounts to 300 cells per μL or more; HIV viral load must be undetectable per standard of care assay, and they must be compliant with antiretroviral treatment.
结局指标
主要结局
The primary endpoint of the phase II part is the 12-month progression-free survival (PFS) rate: the proportion of patients alive and free from progression/post-resection recurrence by 12-months timepoint from randomization (to be considered as primary endpoint in the phase II part of the study and as secondary endpoint in the phase III part of the study).
The primary endpoint of the phase II part is the 12-month progression-free survival (PFS) rate: the proportion of patients alive and free from progression/post-resection recurrence by 12-months timepoint from randomization (to be considered as primary endpoint in the phase II part of the study and as secondary endpoint in the phase III part of the study).
次要结局
- Progression-free survival (PFS), the time from randomization to disease progression, post-resection recurrence or death from any cause
- Event free survival (EFS): the time from randomization to disease progression that precludes definitive surgery, treatment discontinuation for any reason, post-resection recurrence, a second primary cancer, or death from any cause.
- Relapse-free survival (RFS): the time from surgery to disease recurrence or death in patients who undergo to surgery with curative intent.
- Overall survival (OS): the time from randomization to the date of death due to any cause. For patients still alive at the time of analysis, the OS time will be censored on the last date the patients were known to be alive.
- R0 Resection Rate: the percentage of patients, relative to the total of randomized patients, for whom a R0 resection is achieved.
- R0+R1 resection rate, i.e. the percentage of patients, relative to the total of randomized patients, for whom the tumor was macroscopically removed and the intent of surgery is considered curative. Note: R0 surgery is defined as microscopically margin free complete surgical removal of all residual disease. R1 resection indicates the removal of all macroscopic disease, but microscopic margins are positive for tumor.
- Quality of life (QLQ): assessed through Patient Reported Outcome instruments (PROs) distributed by the study staff and completed entirely by the patient. Mean score changes from baseline, proportion of patients with improved, stable, or deteriorated scores from baseline and time to deterioration in the EORTC QLQ-C30 and BIL21 physical functioning, social functioning, and fatigue scores will be compared between the two arms.
- Overall Response Rate (ORR): is defined as the percentage of patients, relative to the total of enrolled subjects receiving neoadjuvant treatment, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria. The determination of clinical response will be based on investigator assessment (during study treatment) and it will be retrospectively evaluated as per blinded independent central review (BICR) of CT scan images.
- Resectability Rate: the retrospective evaluation of patients with unresectable disease, as assessed by the central review committee, in the two arms, and of the rate of conversion to resectability in the neoadjuvant arm.
- Toxicity Rate is defined as the percentage of patients, relative to the total of subjects randomized to receive neoadjuvant treatment, experiencing a specific adverse event, according to National Cancer Institute Common Toxicity Criteria
- Perioperative morbidity and mortality rate is defined as the percentage of patients, with any serious perioperative morbidity or mortality according to Clavien-Dindo classification
研究者
Laura Delliponti
Scientific
Gruppo Oncologico Del Nord Ovest
研究点 (19)
Loading locations...
相似试验
已完成
2 期
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck CancerHead and Neck CancerNCT00337532Bristol-Myers Squibb50
已完成
2 期
Neoadjuvant Pegylated Liposomal Doxorubicin and Cyclophosphamide +/- Trastuzumab Followed by Docetaxel in Breast CancerBreast CancerNCT01206881Herlev Hospital45
已完成
2 期
Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCaBreast CancerNCT01670500Beth Israel Deaconess Medical Center118
终止
2 期
Cisplatin and Nab-paclitaxel for (N2) Defined NSCLCStage IIIA Non-Small Cell Lung CancerNCT02276560UNC Lineberger Comprehensive Cancer Center1
已完成
2 期
Comparison of Neo-adjuvant Weekly Paclitaxel With or Without Carboplatin in Early Breast CancerBreast CancerNCT00919880Tao OUYANG148